NEW: CIBMTR Research
Phase II study of posttransplant cyclophosphamide-based GVHD prophylaxis after HLA-mismatched unrelated donor reduced intensity transplantation: Results from the ACCESS trial expansion cohort
Read more:
🔗 pubmed.ncbi.nlm.nih.gov/42674730/
Phase II study of posttransplant cyclophosphamide-based GVHD prophylaxis after HLA-mismatched unrelated donor reduced intensity transplantation: Results from the ACCESS trial expansion cohort
Read more:
🔗 pubmed.ncbi.nlm.nih.gov/42674730/